1st Quarter - Report

THE MCMANUS GROUP for EMD SERONO, INC.

Firm
Client
Income
$50,000
Expenses
—

What was lobbied

2 issue areas, each in the filer's own words, with who lobbied on it and where.

Health Issues HCR

General pharmaceutical coverage and reimbursement issues, health exchange policy; issues and activities affecting oncology, neurodegenerative and fertility products.

LobbyistCovered position, as disclosed
JOHN MCMANUS —
ALANNA TEMME LD, Rep. Jon Porter
BARRETT THORNHILL —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Medicare/Medicaid MMM

Medicare and Medicaid pharmaceutical coverage and reimbursement issues, particularly regarding neurodegenerative products. Part D reimbursement reform in S. 2543 and H.R. 19/ S. 3129, the Lower Costs, More Cures Act of 2019.

LobbyistCovered position, as disclosed
JOHN MCMANUS —
ALANNA TEMME —
BARRETT THORNHILL —

Contacted: HOUSE OF REPRESENTATIVES; SENATE

Bills named: H.R. 19 (116th), S. 2543 (116th), S. 3129 (116th)

Shown as published by the Senate Office of Public Records and the House Clerk under the Lobbying Disclosure Act. The official filing is the record; open it for the full form.